e.g., PRJCA000229; PRJNA784038; human
Accession PRJCA019575
Title A Proteogenomic Analysis of Cervical Cancer in East Asia Reveals Biological Insights and Therapeutic Signatures
Relevance Medical
Data types Exome
Transcriptome or Gene expression
proteomic, phosphoproteomic, acetylproteomic
Organisms Homo sapiens
Description Cervical cancer remains the fourth most common malignancy and the fourth leading cause of cancer mortality in women. Unlike many other cancers lacking direct etiological association with virus infection, persistent human papillomavirus infection is the central cause of CC, and over 90% of CC patients are associated with HPV infection at the time of diagnosis. Although HPV vaccination may reduce disease risk, CC remains a severe threat to women's health in low- and middle-income countries due to financial constraints and the shortage of HPV vaccine supply . Patients with early-stage CC who are referred for radical hysterectomy with pelvic lymphadenectomy generally have a good prognosis; nevertheless, the five-year overall survival rate of IIB-IVA stage CC patients was only 36.5%. For middle and advanced stage patients, platinum-based chemoradiotherapy is recommended as an effective treatment option. However, the pelvic lymph node is frequently missed during radiotherapy, and CC patients with special pathological subtypes are either not sensitive to radiation or experience substantial side effects, resulting in a poor treatment outcome and a high recurrence rate. There is an urgent need in clinical practice to enhance the efficacy of radiotherapy for advanced patients. Investigating the molecular mechanism of CC development and its HPV association and identifying candidate biomarkers or therapeutic targets could improve individualized diagnosis and therapy for CC, which would greatly improve patient survival and quality of life.In this study, we used CPTAC guidelines(Rodriguez, Zenklusen et al. 2021) to perform integrated genomic, transcriptomic, proteomic, phosphoproteomic, and acetylproteomic analyses on 139 Chinese CC patients. Our proteogenomic study discovered: 1) HPV-promoted phenotypic perturbations at multi-omics levels; 2) proteomic subgroups associated with distinct clinical and biological features; 3) PRKCB as a biomarker for predicting the efficacy of radiotherapy; and 4) acetylation of FOSL2-K222 by EP300 accelerating malignant proliferation. The underlying data presented here serves as a valuable resource for advancing research in various aspects of CC, including biology, diagnosis, treatment strategies, and the exploration of potential therapeutic drugs.
Sample scope Multiisolate
Release date 2024-10-08
Biomaterial provider National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Grants
Agency program Grant ID Grant title
National Key Research and Development Program of China 2022YFA1302900
Shanghai Young Excellent Academic Leader Program 20XD1424900
Submitter Hu Zhou (zhouhu@simm.ac.cn)
Organization Shanghai Institute of Materia Medica
Submission date 2023-09-06

Project Data

Resource name Description
BioSample (287)  show -
GSA-Human (1)-
HRA005516A Proteogenomic Analysis of Cervical Cancer in East Asia Reveals Biological Insights and Therapeutic Signatures
OMIX (1)-
OMIX004882A Proteogenomic Analysis of Cervical Cancer in East Asia Reveals Biological Insights and Therapeutic Signatures